Sciencons As
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Feb 2035
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 13, 2027The maintenance fee for Novel Lead and Thorium Compounds (US 10,377,778) comes due Feb 13, 2027. Unpaid by Aug 13, 2027, it lapses early.
- 1 fee due Apr 8, 2027The maintenance fee for Radiopharmaceutical solutions with advantageous properties (US 10,434,198) comes due Apr 8, 2027. Unpaid by Oct 8, 2027, it lapses early.
Recent changes
- 2 of the patents on this record were granted since Aug 21, 2026
- Nov 17 US 12,802,834 Production of Highly Purified 212PB
- Nov 10 US 12,793,867 Production of Highly Purified 212PB
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,433,690 | Radiopharmaceutical solutions with advantageous properties In force · USPTO record | In force | USPTO record | |
| US 10,434,198 | Radiopharmaceutical solutions with advantageous properties In force · USPTO record | In force | USPTO record | |
| US 11,306,038 | Preparation of 212PB Labeled Monoclonal Antibodies In force · High confidence | In force | High confidence | |
| US 10,377,778 | Novel Lead and Thorium Compounds In force · High confidence | In force | High confidence | |
| US 12,297,218 | Complex Comprising a Psma-Targeting Compound Linked to a Lead or Thorium Radionuclide In force · High confidence | In force | High confidence | |
| US 12,249,437 | Production of Highly Purified 212PB In force · High confidence | In force | High confidence | |
| US 12,394,533 | Production of Highly Purified 212PB In force · Medium confidence | In force | Medium confidence | |
| US 12,406,776 | Production of Highly Purified 212PB In force · High confidence | In force | High confidence | |
| US 12,567,511 | Production of Highly Purified 212PB In force · High confidence | In force | High confidence | |
| US 12,793,867 | Production of Highly Purified 212PB In force · High confidence | In force | High confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
7 pending · 2 abandoned
Showing 1 to 9 of 9, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page.
| Application | Title | Filed | Status |
|---|---|---|---|
| 19/262,158 | Production of Highly Purified 212PB | Jul 8, 2025 | Pending |
| 19/262,153 | Production of Highly Purified 212PB | Jul 8, 2025 | Pending |
| 19/262,147 | Production of Highly Purified 212PB | Jul 8, 2025 | Pending |
| 18/940,751 | Production Of Highly Purified 212PB | Nov 7, 2024 | Pending |
| 18/940,735 | Production of Highly Purified 212PB | Nov 7, 2024 | Pending |
| 18/940,734 | Production of Highly Purified 212PB | Nov 7, 2024 | Pending |
| 18/628,420 | Complex Comprising a Psma-Targeting Compound Linked to a Lead or Thorium Radionuclide | Apr 5, 2024 | Abandoned |
| 18/729,758 | Complexes for Cancer Treatment and Imaging | Jan 20, 2023 | Pending |
| 16/771,596 | Complex Comprising a Psma-Targeting Compound Linked to a Lead or Thorium Radionuclide | Dec 13, 2018 | Abandoned |